NCT06042998 A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer
| NCT ID | NCT06042998 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Affiliated Hospital of Qingdao University |
| Condition | Gastric Cancer Stage II |
| Study Type | INTERVENTIONAL |
| Enrollment | 588 participants |
| Start Date | 2023-07-07 |
| Primary Completion | 2024-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 588 participants in total. It began in 2023-07-07 with a primary completion date of 2024-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the clinical efficacy of robot radical Gastrectomy and laparoscopic radical Gastrectomy, patients with gastric adenocarcinoma (cT2N+M0 or cT3-4a/N+M0, phase II and III) undergoing neoadjuvant treatment were selected as subjects.
Eligibility Criteria
Inclusion Criteria: 1. 18 years old ≤ 75 years old male or female; 2. The primary gastric lesion was diagnosed as gastric adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, Signet ring cell carcinoma, poorly differentiated adenocarcinoma) by endoscopic biopsy histopathology; 3. Before neoadjuvant treatment, the preoperative clinical staging was confirmed to be II and III (cT2N+M0 or cT3-4a/N+M0) through gastroscopy/ultrasound gastroscopy, enhanced CT/MR, or diagnostic laparoscopic exploration (based on AJCC-8th TNM tumor staging); 4. 2-4 cycles of neoadjuvant therapy (chemotherapy+/- targeted/immunotherapy, simple chemotherapy); 5. After new adjuvant treatment, radical Gastrectomy is feasible after MDT discussion; 6. Preoperative ECOG physical condition score of 0/1 or Karst score ≥ 70%; 7. Preoperative ASA score I-III; 8. The expected survival period exceeds 6 months; 9. Willing and able to comply with the research protocol; 10. Sign a written informed consent form before enrollment and be fully aware of the right to withdraw from this study at any time. Exclusion Criteria: 1. Pregnant or lactating women; 2. Suffering from serious mental illness; 3. History of upper abdominal surgery (excluding history of laparoscopic cholecystectomy); 4. History of gastric surgery (excluding ESD/EMR for gastric cancer); 5. Moderate to severe renal insufficiency; 6. Organ transplant recipients receiving immunosuppressive therapy; 7. Have a history of other malignant diseases within 5 years; 8. Have a history of unstable angina or myocardial infarction within 6 months; 9. Have a history of cerebral infarction or cerebral hemorrhage within 6 months; 10. Have a history of continuous systemic corticosteroid therapy within one month; 11. Simultaneous surgical treatment of other diseases is required (excluding laparoscopic cholecystectomy); 12. Gastric cancer comorbidities (bleeding, perforation, obstruction) requiring emergency surgery; 13. Lung function test FEV1\<50% of expected value; 14. The patient has participated or is currently participating in other clinical studies (within 6 months).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06042998 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Gastric Cancer Stage II. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06042998 currently recruiting?
Yes, NCT06042998 is actively recruiting participants. Contact the research team at zhouyanbing999@aliyun.com for enrollment information.
Where is the NCT06042998 trial being conducted?
This trial is being conducted at Qingdao, China.
Who is sponsoring the NCT06042998 clinical trial?
NCT06042998 is sponsored by The Affiliated Hospital of Qingdao University. The trial plans to enroll 588 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.